Oncology Search
Oncology Oncology
cancer%20pain
CANCER PAIN
Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.

Introduction

  • Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival
    • Chronic pain syndrome also often occurs following cancer treatments
  • Pancreatic, head & neck cancer has a high prevalence of cancer pain
  • During initial evaluation, follow-ups & new therapy initiation of patients with cancer, it is essential that they be screened & evaluated for pain

Definition

  • An unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
A report of the first patient in Malaysia who had successfully completed 16 cycles of brentuximab vedotin
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
Hodgkin's lymphoma patients experience fatigue even after treatment
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Measurable residual disease in AML: Reduced-intensity conditioning associated with poorer post-transplant outcomes
Natalia Reoutova, 16 Jul 2019
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.